The DCGI approved Bharat Biotech's first intranasal Covid vaccine on Tuesday for use as the first line of defence against the infection in adults over the age of 18. Health Minister Dr. Mansukh Mandaviya praised the accomplishment, calling it a "Big Boost to India's Fight Against COVID-19." “Big Boost to India's Fight Against COVID-19! Bharat Biotech's ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in 18+ age group for restricted use in emergency situation,” Dr. Mansukh Mandaviya tweeted. According to a statement from BBIL, it has shown to be secure, well-tolerated, and immunogenic in test subjects. According to the firm, national regulatory authorities have received the data from both of the Phase III human clinical trials that have been filed for approval.

Key Points

• The DCGI approved Bharat Biotech's first intranasal Covid vaccine on Tuesday for use as the first line of defence against the infection in adults over the age of 18.

• According to the firm, national regulatory authorities have received the data from both of the Phase III human clinical trials that have been filed for approval.